top of page


Cancer52 welcomes NHS Long Term Plan
This is an ambitious plan by NHS England to move more care into the community and out of hospital, accompanied by increased funding for...


A short film of patient voices
As the NHS Long Term Plan is published - some messages of hope from people with rare and less common cancer for 2019 and beyond …. a...

What the National Data Opt-out means for cancer patients
Cancer52, together with use MY data, have jointly produced a briefing document on what The National Data Opt-out means for cancer...

Cancer52 in the New Statesman
We are delighted that Cancer52 features in this month's New Statesman's Oncology Supplement, published to coincide with this year's...
Cancer52 Trustee Recruitment
We are pleased to announce that Cancer52 is recruiting trustees to its board to support the future development and growth of the...
Cancer52 film on PHE website
In June, at the PHE Cancer Services, Data and Outcomes Conference 2018, Cancer52 worked with the National Cancer Registration and...

Getting a better deal for people with rare and less common cancers: the next ten years
We're excited to announce the publication of our new briefing document 'Getting a better deal for people with rare and less common...
The UK team has crossed the finish line of the C2C4C challenge!
Yesterday afternoon, the Bristol-Myers Squibb (BMS) UK team cycled into Uxbridge, marking the end of this year’s Country 2 Country 4...
One week into the C2C4C challenge and the UK team are raring to go!
We are now over one week into this years’ Bristol-Myers Squibb (BMS) Country 2 Country 4 Cancer (C2C4C) cycling challenge, meaning we are...
This year’s #C2C4Cancer bike ride has begun!
This Monday, the Bristol-Myers Squibb (BMS) Country 2 Country 4 Cancer (C2C4C) bike ride set off for another year. It's a pan-European...
bottom of page